Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 3/20 | 0.32 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604542 | 0.88 | ALDH1A1 (0.35) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3617930 | 0.86 | ALDH1A1 (0.34) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3621354 | 0.86 | ALDH1A1 (0.34) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3619979 | 0.85 | HSD17B10 (0.35) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3618996 | 0.84 | HPGDS (0.39) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3613305 | 0.84 | ALDH1A1 (0.33) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL14763113 | 0.76 | ALDH1A1 (0.42) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL6171280 | 0.76 | ALDH1A1 (0.33) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL533577 | 0.75 | SCN9A (0.34) | ALDH1A1F2GLAHPGDSCN9A | |
| SCHEMBL14763154 | 0.75 | ALDH1A1 (0.41) | HPGDSALDH1A1F2GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2139324-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | Syngeta Participations AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008110355-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | CYP1A1, CYP4X1, CYP3A7 | HPGDS 4855/4885ALDH1A1 350/4885F2 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.